Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies

Pegylated liposomal doxorubicin (PLD) is a palliative treatment option for patients with recurrent gynecologic malignancies. It has an appealing toxicity profile and responses can be prolonged. There is no consensus as to the level of cardiac toxicity. Current label warnings, National Comprehensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Yost, S., Konal, J.L., Hoekstra, A.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710555/
https://www.ncbi.nlm.nih.gov/pubmed/31467958
http://dx.doi.org/10.1016/j.gore.2019.07.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710555/
https://www.ncbi.nlm.nih.gov/pubmed/31467958
http://dx.doi.org/10.1016/j.gore.2019.07.012

Ejemplares similares